An entry written while the outcome is still unknown. It will be scored by what the market does next, and it will never be edited to look cleverer than it was.
In plain words · CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States.
VERDICT
The label
Markup
read at $74.85
CG Oncology, Inc. holds its Markup at $74.85.
PHPhase · the trend structure carries the Markup label
POPositioning · no disclosures inside 60 days, left as found
OPOptions · no verdict drawn today, left as found
SCScreen · does not pass the values gate
edge confirmed
edge broken
edge forming
Each arm is one independent read. Conviction is not a single call, it is how many edges converge.
INVESTOR
The investor read · the season, not the day
As held on the ledger · 2026-08-06
Phase
Markup
Quantitative state
Elevated stress, defensive posture warranted, held for 16 days
Price
$74.85
Valuation
N/A trailing · -27.23 forward price to earnings
Values screen
FAIL· score 70.0
Beta
0.23
OPPORTUNITY
The opportunity · what the numbers say it is worth
Read at
$74.85
N/A P/E · -27.23 fwd
Our fair value
$90.00
20% discount
Analyst target (avg)
$90.00
+20% to current
Target low $80.00Analyst target rangeTarget high $108.00
▲ current $74.85 · | average target
Price history & projections · where it has been, where the models see it going
The valuation journey · where the price sits against fair value and the Street
Current
$74.85
you are here
Conservative
$80.00
+7%
Analyst avg
$90.00
+20%
Our fair value
$90.00
+20%
Analyst high
$108.00
+44%
Green marks levels above today's price, red below; the shaded band is the gap between the price and our fair value.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Revenue growth
1,982.70%
Profit margin
0.00%
Debt to equity
0.69
Analyst consensus
Strong Buy · 13 covering
Fair value and rating are our own model estimates; target range reflects third-party analyst estimates. Analysis, not advice.
SCREEN
The values screen, explained · five checks, plain English
This company is excluded by both standards. There are two widely recognised ways to check whether a company is suitable for a Muslim investor. It fails on both:
The common standard· AAOIFI Used by most halal investing apps✗ DOES NOT PASS
Our stricter standard· asset-based The one Titan applies✗ DOES NOT PASS
Why it fails. The problem is its interest-bearing securities. Because both standards agree on this, it is a clear exclusion, not a borderline case.
Business activityIts core business isn't built on prohibited lines — no gambling, alcohol, tobacco, weapons, or interest-based lending.Pass
Debt loadInterest-bearing debt is just 0.9% of its assets, well under the one-third ceiling — it does not run on borrowed money.Pass
Interest-bearing cashInterest-bearing cash and securities are 89.7% of assets, above the one-third limit.Fail
ReceivablesMoney owed to the company is 4.2% of assets, under the 49% limit.Pass
Revenue purity740.9% of revenue comes from non-compliant sources, over the 5% line.Fail
Every security is read against two recognised standards: our stricter asset-based screen (ratios measured against total assets) and the more widely used market-value standard (measured against market capitalisation). Where they agree we say so plainly; where they part ways — almost always on the debt check — we show both readings and mark it, because that disagreement is the finding, not a fault. We report the score; you and your scholar make the call.
PLAIN
The business, in plain words · what the numbers mean
One Drug Bet On Bladder Cancer Therapy
A patient facing recurring bladder cancer waits for a therapy that might finally work, yet this company is still years from selling anything at all. Revenue is exploding from a tiny base but the business posts no profit and a deeply negative return on equity, so the valuation sits on hope rather than cash flow.
We pass because the opportunity rating is none despite the analyst target near fair value. An unknown moat, zero profit margin and a forward price to earnings ratio that is deeply negative leave too little substance for a durable investment case in a field where most candidates fail.
The real risk is binary clinical or regulatory disappointment that could erase most of the value overnight, with currency and dilution pressures adding to the volatility typical of pre-commercial biotech. Analysis, not advice.
Screened names in the same industry · explore each on its own page.
TRADE
Where & how to trade · wherever in the world you are
CGON trades on Nasdaq. As a US-listed security it is accessible through almost any international broker offering US markets. New to this, or investing from outside the US? Our guide to accessing global markets covers brokers, currencies and the practical steps.
TRADER
The trader read · the latest dated commentary
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 20.6% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 23% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 100%. Our forward projection puts the odds of a 10% gain over the next month near 35%. The street (14 analysts) rates it strong buy, with a mean price target of $90. Insiders have been net buyers over the past quarter. Entered 2026-07-24 · Markdown
JOURNAL
The dated journal · newest first, never edited
2026-07-24Markdown$71.85+20.6%Entry 4
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 20.6% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 23% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 100%. Our forward projection puts the odds of a 10% gain over the next month near 35%. The street (14 analysts) rates it strong buy, with a mean price target of $90. Insiders have been net buyers over the past quarter.
2026-07-18Markdown$59.56+0.0%Entry 3
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 23% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 100%. Our forward projection puts the odds of a 10% gain over the next month near 35%. The street (14 analysts) rates it strong buy, with a mean price target of $90.
2026-07-03Markdown$59.56+0.0%Entry 2
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.
2026-07-02Markdown$59.56Entry 1
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
